Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Suleman

Surgery Kenner, LA Medical Doctor

NPI 1619972536 CMS profile 254698

200 W Esplanade Ave, Ste 312, Kenner, LA 70065

Open in the dashboard

General payments

$1,181

41 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Suleman of Kenner, LA is reported in the CMS Open Payments database as having received $1,181 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $102 4
2024 General $225 5
2023 General $168 5
2022 General $98 5
2021 General $149 4
2020 General $93 5
2019 General $347 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Suleman
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Mohammed Suleman were reported at $102. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Mohammed Suleman Surgery median Middle half National median
2019 $347 $253 $82–$1,521 $163
2020 $93 $131 $40–$706 $114
2021 $149 $168 $50–$904 $132
2022 $98 $224 $76–$1,218 $149
2023 $168 $253 $82–$1,255 $160
2024 $225 $279 $90–$1,381 $164
2025 $102 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $210 9 payments
  2. Bard Peripheral Vascular, Inc. $150 1 payment
  3. Organogenesis Inc. $134 2 payments
  4. AbbVie, Inc. $116 2 payments
  5. Kerecis Limited $77 2 payments
  6. KCI USA, Inc $68 3 payments
  7. Bioventus LLC $63 3 payments
  8. Acera Surgical, Inc. $55 2 payments
  9. Lilly USA, LLC $39 2 payments
  10. Novo Nordisk Inc $35 2 payments
  11. Other $236 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,181 41 payments
Products named General payments · program years 2019–2025
  1. LUTONIX $150 1 payment
  2. DALVANCE $143 4 payments
  3. COLLAGENASE SANTYL $89 3 payments
  4. Kerecis Omega3 SurgiClose Wound Care $77 2 payments
  5. Kerecis Omega3 GraftGuide $77 2 payments
  6. VAC VERAFLO $68 3 payments
  7. STRAVIX PL $56 2 payments
  8. Restrata Wound Matrix $55 2 payments
  9. Kerecis Omega3 SurgiClose Wound Care $52 1 payment
  10. Kerecis Omega3 Marigen $52 1 payment
  11. Other $569 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

644

Median for Vascular Surgery: 122

Drug cost

$37,789

Median for Vascular Surgery: $14,135

Branded share of claims

39.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 59 $25,745
Gentamicin Sulfate Generic 61 $4,633
Mupirocin Generic 168 $1,958
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 48 $807
Doxycycline Hyclate Generic 32 $671
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 26 $577
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 32 $556
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 62 $553
Ciprofloxacin Hcl Generic 20 $520
Lidocaine Generic 17 $509

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$31,913

Medicare's payments for the services billed

Medicare patients

72

Average age 71

Services billed

542

31 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 54%
Chronic kidney disease 51%
Arthritis 47%
Heart failure 33%
Ischemic heart disease 33%
Atrial fibrillation 28%
Osteoporosis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record